Comment
doi: 10.1016/S1473-3099(18)30217-2.
Colistin versus colistin plus meropenem for severe infections
Affiliations
- PMID: 29695357
- DOI: 10.1016/S1473-3099(18)30217-2
Item in Clipboard
Comment
Colistin versus colistin plus meropenem for severe infections
Lancet Infect Dis.
2018 May.
No abstract available
Comment in
-
Colistin versus colistin plus meropenem for severe infections Authors' reply.Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. Lancet Infect Dis. 2018. PMID: 29695358 No abstract available.
Comment on
-
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16. Lancet Infect Dis. 2018. PMID: 29456043 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
